Synthesis and bioactivity of new Finasteride conjugate.
Bioorg Med Chem Lett
; 21(11): 3439-42, 2011 Jun 01.
Article
en En
| MEDLINE
| ID: mdl-21515045
ABSTRACT
Finasteride is a synthetic 4-azasteroid compound that acts by inhibiting type II 5α-reductase, the enzyme that converts the androgen testosterone to 5α-dihydrotestosterone. It was approved by the US FDA for the treatment of benign prostatic hyperplasia and male pattern baldness. Here the acylation product of Finasteride C-18 amide N-polimod was synthesized by employing acylation reaction with polimod amide as a pivotal intermediate. The structure of the key intermediate and target molecule was confirmed by infrared spectrum, (1)H NMR and (13)C NMR spectra and mass spectrum, and the inhibition of the steroid 5α-reductase and the rats' benign prostatic hyperplasia by the new Finasteride conjugate and Finasteride was also determined. The inhibition of the Finasteride conjugate on 5α-reductase was stronger than that of Finasteride. Prostate hyperplasia of rats was reduced by Finasteride conjugate treatment similar to the Finasteride treatment. However, the Finasteride conjugate treated animals showed better viable condition than the Finasteride treated ones, suggesting the new compound may have improved toxicity profile than Finasteride.
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Finasterida
/
Inhibidores de 5-alfa-Reductasa
Límite:
Animals
Idioma:
En
Año:
2011
Tipo del documento:
Article